More articles about Clinical Lab Management

The partners aim to develop jointly-branded clinical decision support software for faster, more accurate, and more confident decision-making.

By dropping the cutoff value in urine immunoassay testing to 20 from 100, the researchers reduced the false-negative rate to 2 percent from 47 percent.

Quest will have a broader relationship with Cleveland Clinic in diagnostic development, the companies say.

The potential effect of new, lower PAMA prices remains a key issue facing both companies, the investment bank said.

The court's modified ruling allows laboratories to rely on an ordering physician's determination of medical necessity.

The fully automated, random access calprotectin assay can help clinicians differentiate irritable bowel disease from irritable bowel syndrome.

There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition. 

Dominion Diagnostics will pay $815,000 to settle allegations by the US Attorney's Office and Vermont that it improperly billed for tests.

With common lab tests under pressure from PAMA pricing, some analysts say labs should shift to more esoteric testing anyway.

The carrier helps diagnostic companies to defray evidence development costs by covering experimental diagnostics on a trial basis.

The suits allege that the company issued false or misleading statements and seek to recover damages for investors.

AdvaMed's VP of payment and healthcare delivery policy said that the framework promotes a broad definition and understanding of value.  

Increased consumer interest in prenatal health is also spurring use of carrier screening for genetic conditions.

The suit filed against the acting HHS secretary alleges that a flawed data collection process failed to establish market-based rates.

Through the new lab, NeoGenomics can work with pharmaceutical clients through the different phases of drug development, including the development of companion diagnostics.

As part of the acquisition, Quest has formalized an R&D agreement with Cleveland Clinic to commercialize emerging innovations.

The Gaithersburg, Maryland-based pathology practice is Aurora's fifth pathology practice acquisition in 2017.

The FDA's warning comes after one reported death related to biotin interference with troponin test results.

Mass spectrometry cerebral spinal fluid assay can help differentiate between Alzheimer's and other forms of dementia, Quest says

Lipid panel prices and prices for tests formerly bundled together as automated testing profiles are expected to rise in 2018, but fall in 2019.

Pages